Samuel P Arnot1, Gang Han2, Jeanine Fortino1, Dale Han1, Graham Fowler1, John T Vetto3. 1. Department of Surgery, Division of Surgical Oncology, Oregon Health & Science University, Portland, OR, USA. 2. School of Public Health, Texas A and M University, College Station, TX, USA. 3. Department of Surgery, Division of Surgical Oncology, Oregon Health & Science University, Portland, OR, USA. Electronic address: vettoj@ohsu.edu.
Abstract
BACKGROUND: A 31-gene genetic expression profile (31-GEP; Class 1 = low risk, Class 2 = high risk) developed to predict outcome in cutaneous melanoma (CM) has been validated by retrospective, industry-sponsored, or small series. METHODS: Tumor features, sentinel node biopsy (SNB) results, and outcomes were extracted from a prospective database of 383 C M patients who underwent SNB and had a 31-GEP run on their primary tumor. Groups were compared by uni- and multi-variable analysis. Relapse-free and distant metastasis-free survival (RFS, DMFS) were estimated by Kaplan-Meier method. RESULTS: Breslow thickness, T stage, and SNB positivity were significantly higher in Class 2 patients. Recurrence rates were higher for Class 2 vs Class 1 patients and highest in patients who were Class 2 and SNB positive. GEP class was predictive of RFS and DMFS and independently predicted relapse in AJCC "low risk" (stages IA-IIA) patients. CONCLUSIONS: 31-GEP adds prognostic information in CM patents undergoing SNB.
BACKGROUND: A 31-gene genetic expression profile (31-GEP; Class 1 = low risk, Class 2 = high risk) developed to predict outcome in cutaneous melanoma (CM) has been validated by retrospective, industry-sponsored, or small series. METHODS:Tumor features, sentinel node biopsy (SNB) results, and outcomes were extracted from a prospective database of 383 C M patients who underwent SNB and had a 31-GEP run on their primary tumor. Groups were compared by uni- and multi-variable analysis. Relapse-free and distant metastasis-free survival (RFS, DMFS) were estimated by Kaplan-Meier method. RESULTS: Breslow thickness, T stage, and SNB positivity were significantly higher in Class 2 patients. Recurrence rates were higher for Class 2 vs Class 1 patients and highest in patients who were Class 2 and SNB positive. GEP class was predictive of RFS and DMFS and independently predicted relapse in AJCC "low risk" (stages IA-IIA) patients. CONCLUSIONS: 31-GEP adds prognostic information in CM patents undergoing SNB.
Authors: Sebastian Podlipnik; Aram Boada; Jose L López-Estebaranz; Manuel M Martín-González; Pedro Redondo; Brian Martin; Ann P Quick; Christine N Bailey; Sarah J Kurley; Robert W Cook; Susana Puig Journal: Cancers (Basel) Date: 2022-02-19 Impact factor: 6.639
Authors: Oliver J Wisco; Justin W Marson; Graham H Litchman; Nicholas Brownstone; Kyle R Covington; Brian J Martin; Ann P Quick; Jennifer J Siegel; Hillary G Caruso; Robert W Cook; Richard R Winkelmann; Darrell S Rigel Journal: Melanoma Res Date: 2022-04-01 Impact factor: 3.199
Authors: Aaron S Farberg; Justin W Marson; Alex Glazer; Graham H Litchman; Ryan Svoboda; Richard R Winkelmann; Nicholas Brownstone; Darrell S Rigel Journal: Dermatol Ther (Heidelb) Date: 2022-03-30